Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Catheter Precision ( (VTAK) ) has provided an announcement.
On June 5, 2025, Catheter Precision, Inc.’s Board of Directors approved a warrant issuance to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to the company’s pipe financing closed on May 12, 2025. This warrant allows the purchase of 257,143 shares at $0.5424 per share, pending stockholder approval at the annual meeting on July 25, 2025. The warrant will expire on June 6, 2030, and neither it nor the underlying shares have been registered under the Securities Act of 1933.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
VTAK faces significant financial challenges with persistent losses and negative cash flows. Technical indicators reflect a bearish trend, and the valuation is unfavorable due to a lack of earnings. Corporate events further add to uncertainty, impacting investor confidence.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 585,487
Technical Sentiment Signal: Sell
Current Market Cap: $2.33M
Learn more about VTAK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue